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ABSTRACT
The anti-arthritic drug auranofin exerts also potent antitumour activity in in vitro 
and in vivo models, whose mechanisms are not yet well defined. From an auranofin-
sensitive human ovarian cancer cell line A2780, a highly resistant (>20-fold) 
subline (A2780/AF-R) was developed and characterized. Marked reduction of gold 
accumulation occurred in auranofin-resistant A2780 cells. Also, moderately higher 
thioredoxin reductase activity in A2780/AF-R cells was observed while no changes 
in intracellular glutathione content occurred. Resistance to auranofin was associated 
with a low level of cross-resistance to some investigational gold compounds as well as 
to oxaliplatin and other anticancer drugs with different mode of action (i.e. melphalan, 
vinblastine, doxorubicin, etoposide, and paclitaxel). Reduced gold accumulation was 
associated to substantial gene expression changes in various influx (e.g. SLC22A1, 
SLC47A1, SLCO1B1) and efflux (e.g. ABCB1, ABCC2, ABCC3) transporters. The 
expression levels of selected proteins (i.e. SLC22A1, SLC47A1, P-gp) were also 
changed accordingly. These data provide evidence that multiple drug transporters 
may act as mediators of transport of auranofin and other gold compounds in cancer 
cells. Further investigation into the molecular mechanisms mediating transport of 
auranofin and new gold complexes in view of their potential clinical application in the 
treatment of cancer is warranted.
INTRODUCTION
Auranofin, an oral gold (I) compound, was developed 
in the 1980’s for the treatment of rheumatoid arthritis [1]. 
Despite its appreciable efficacy in the treatment of this 
disease, auranofin is at present rarely used in the clinic since 
novel and more effective anti-rheumatic drugs have become 
available [2, 3]. Yet, auranofin in recent years has shown 
promise in the treatment of several different diseases, 
including cancer. Preclinical evidence in various tumour 
models [4-7] have contributed to the implementation of 
clinical trials of auranofin in different types of tumours 
(e.g. leukaemia, ovarian cancer and other solid tumours) 
[8]. Most of these studies are based on programs of drug 
repurposing promoted by the National Institute of Health 
(NIH) [9] and other institutions [10, 11].
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It is now ascertained that auranofin exerts potent 
antineoplastic activity in various in vitro and in vivo 
tumour models [12-14]. It also represents a reference 
compound when new gold-based compounds are studied 
as potential anticancer drugs.
The mechanism of action of auranofin in cancer 
is not fully understood. Auranofin was shown to cause 
a dose-dependent inhibition on DNA, RNA and protein 
synthesis in human tumour Hela cells and murine B16 
tumour cells at cytotoxic concentrations [4, 5]. However, 
subsequent studies investigating the role of DNA 
replicative enzymes failed to show that the inhibition of 
DNA replication is a critical factor in the cytotoxicity of 
this agent [15]. Thus, it was recognized that auranofin 
may interact with several other cellular macromolecules 
leading to injures to diverse cell structures and inhibition 
of a number of essential signalling pathways involved 
in the progression of cancer [12, 16]. However, unlike 
cisplatin, extensive evidence showed that cytotoxicity of 
auranofin is not due to a direct interaction with DNA [17].
The antineoplastic activity of auranofin relies on 
inhibition of cell proliferation by induction of apoptotic 
cell death and block of tumour neoangiogenesis [12, 
13]. Auranofin was shown to induce apoptosis in several 
different cancer cell lines through increased production of 
reactive oxygen species and by modification of cell redox 
status [18, 19]. In addition, as other gold compounds, 
auranofin inhibits mitochondrial [20] and cytosolic [21] 
thioredoxin reductase leading to oxidative stress including 
peroxiredoxin 3 oxidation [18], and consequent cellular 
accumulation of H2O2 which triggers Bax-Bak-dependent 
apoptosis [18, 22]. A further consequence of thioredoxin 
reductase inhibition is the disruption of selenoprotein 
synthesis that leads to the disruption of DNA synthesis [23].
Also, auranofin inhibits several tumour signalling 
pathways, independent pro-inflammatory and 
neoangiogenesis pathways, contributing to the control of 
cancer growth and progression [13]. As several other gold 
compounds, it has been suggested that auranofin targets the 
proteasome [12]. Notably, in tumour cells, auranofin does 
not inhibit the three main catalytic peptidase activities of 
purified 20S proteasome [24] but inhibits 19S proteasome-
associated deubiquitinases, consequently inducing cell 
apoptosis [25, 26]. Overall, these observations suggest for 
auranofin a complex and multifactorial mode of action.
To further improve the understanding of the 
molecular mechanisms of auranofin cytotoxicity as well 
as to unravel the mechanisms responsible for resistance 
to gold compounds, the development and characterization 
of auranofin-resistant cell lines may be useful. Very few 
studies have so far addressed these issues [27, 28] and 
none of them were accomplished in human tumour cell 
lines. Indeed, experimental studies using relevant in vitro 
and in vivo models of drug-resistance and drug-sensitive 
human cancer may lead to improved knowledge of the 
mechanisms of action and resistance of gold compounds as 
well as of the strategies to develop gold-based analogues 
of potential clinical utility.
We describe here the development and 
characterization of an auranofin-resistant human ovarian 
cancer cell line (A2780/AF-R) which was established 
from an auranofin-sensitive parental cell line (A2780). 
Properties of this resistant line were compared with 
those of the parental line. Resistance to auranofin 
and cross-resistance to several other drugs including 
recently synthesized gold (I) and (III) compounds, were 
determined. Furthermore, in these cell lines, we examined 
differences in cellular gold content and in the expression 
of proteins potentially involved in cell influx/efflux of 
auranofin as well as the potential reversion of auranofin 
resistance by verapamil.
RESULTS
Characteristics of the auranofin resistant cell line
Parental A2780 cells were cultured in the continuous 
presence of stepwise increasing auranofin concentrations. 
Following a six-step rise of auranofin concentrations from 
0.1 to 7.0 μM in 8 months, a resistant subline was obtained 
(A2780/AF-R). At this stage, a resistance index (RI) of 
about 22-fold was obtained and the selected cells were 
able to grow at 7 μM auranofin, a concentration at which 
no cells of the parental line survive. In monolayer culture 
the A2780/AF-R cell line had a doubling time similar to 
that of the parental A2780 cell line (22.60 ± 2.58 and 19.70 
± 4.66 hours, respectively). Periodic IC50 determinations 
showed that the degree of auranofin resistance in the 
A2780/AF-R cell line was stable, during a 3-month period 
of subculture in drug-free medium (RI 20.7, 18.0 and 18.7 
at 1, 2 and 3 months, respectively).
Cross-resistance studies
An analysis of the pattern of sensitivity/resistance 
to other gold (I or III)–based compounds of more 
recent synthesis (Auoxo6, Au2Phen2, Aubipy
c, AuL12, 
Au(NHC)Cl and Au(NHC)2) (Figure 1) was performed 
by concurrent comparisons of drug IC50 values of the 
auranofin resistant A2780 subline (A2780/AF-R) with 
those of the parental auranofin sensitive A2780 cell line. 
Only Au2Phen2 was more active, on a micromolar basis, 
than auranofin. In the sensitive cell line the relative degree 
of cytotoxicity was Au2Phen2>auranofin>Au(NHC)2> 
Au(NHC)Cl>Auoxo6>Aubipyc>AuL12 (most to least 
active) (Figure 2A).
The development of primary resistance to auranofin 
in vitro also resulted in a low level of cross-resistance to 
three of the tested gold compounds (Aubipyc, Au2Phen2, and 
Au(NHC)Cl, cross-resistance index (CRI) of 2.5, 3.6 and 
2.7, respectively) but not to other three gold-compounds 
(Auoxo6, AuL12, and Au(NHC)2) after a 72-hour exposure. 
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The latter compounds were able to completely circumvent 
resistance to auranofin (CRI <1.5) (Figure 2A).
Cross-resistance to other drugs commonly used 
in ovarian cancer therapy was assessed by concurrent 
comparisons of the IC50 values of the resistant subline 
with those of the parental line. Cross-resistance to these 
drugs variably accompanied development of in vitro 
primary resistance to auranofin in this line. The A2780/
AF-R subline was modestly cross-resistant to oxaliplatin, 
melphalan, etoposide, vinblastine, doxorubicin and 
paclitaxel (CRI from 3.9 to 2.1, respectively). No cross-
resistance to cisplatin, carboplatin and docetaxel was 
demonstrated (CRI≤1.5) (Figure 2B).
Cellular gold accumulation
To investigate whether resistance to auranofin 
in A2780/AF-R was related to a decrease in drug 
accumulation, cellular gold content was determined during 
an 8-hour exposure to 10 μM auranofin in both A2780/
AF-R and A2780 (Figure 3). When auranofin cellular 
accumulation was examined, a substantial reduction in 
the content and in the AUC of gold was found in A2780/
AF-R cells compared to that in A2780 sensitive cells 
(338.0 pmol/106 cells vs 4630.0 pmol/106 cells at 480 min, 
respectively, i.e. an 86.3% reduction; AUC0-8hr 1.3x10
3 
vs 3.5x104 pmol x hr/106 cells, respectively, i.e. a 96.3% 
reduction). The accumulation of cellular gold was rapid 
and reached a plateau at about 120 min in A2780 cells. In 
contrast, the accumulation of cellular gold was dismal and 
displayed a linear kinetics during the entire drug exposure 
time in A2780/AF-R cells.
mRNA expression levels of transport and 
trafficking pathway genes in A2780/AF-R and 
A2780
To verify whether changes in the expression 
of transport and trafficking pathway genes might be 
associated to the observed reduced gold accumulation 
in auranofin resistant cells, mRNA expression levels of 
candidate genes were measured in A2780/AF-R and 
A2780 cells. Overall, changes in mRNA expression of 13 
out of 24 evaluated genes in A2780/AF-R cells compared 
to A2780 cells were observed. Seven were up-regulated 
(from 3.3 to > 2x106-folds) and 6 down-regulated genes 
(from 3.4 to 1.4x103-folds) (Figure 4, Table 1).
Among genes belonging to the solute carrier family 
(SLC), a 21.9-fold decrease and a 1.2x103-fold increase 
of mRNA levels of the organic cation transporter genes 
SLC22A1 and SLC22A3, respectively, was observed in 
A2780/AF-R cells compared to the A2780 cells. Also, a 
6.3-fold increase in the mRNA expression of the copper 
transporter protein SLC31A2 was observed in A2780/
AF-R cells compared to A2780 cells and a 1.4x103-fold 
decrease of mRNA level of the multidrug/toxin extrusion 
transporter SLC47A1 was observed in A2780/AF-R. No 
significant changes were observed in the other 3 solute 
carrier family genes analysed.
A substantial increase in mRNA expression levels 
of the ATP binding cassette transporters ABCB1, ABCC2 
and ABCC3 (from 48 to >1x106 folds) was observed in the 
resistant cell line compared with the sensitive one whereas 
a decrease of about 11-fold was observed in the mRNA 
of ABCG2 in the auranofin resistant cell line. The highest 
Figure 1: Chemical structures of gold (I) and gold (III) compounds.
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increase was observed in ABCC3, as a consequence of its 
almost undetectable expression level in A2780 cells.
No substantial difference was observed between the 
expression of the copper transporters ATP7A and ATP7B 
or the Na+/K+ ATPase transporters ATP1A1 and ATP1A2 
between the two cell lines with the exception of a 11.6-
fold decrease in mRNA expression levels of ATP1A3 in 
the resistant cell line compared with the sensitive one. No 
mRNA expression difference was observed for ATOX1.
Among CLT genes that mediate endocytosis, an 
about 3-fold increase in CLTB and CLTD gene expression 
was observed in the auranofin resistant cell line. An about 
3-fold decrease was observed in PIK3CA expression in 
A2780/AF-R cells as compared to A2780 cells.
Protein levels of selected relevant transporters
To determine whether the observed variations 
in mRNA levels of selected relevant transporters were 
correlated with variations at protein levels, Western blotting 
analysis of SLC22A1, SLC47A1 and P-gp was performed 
in A2780 and A2780/AF-R cells. Although less markedly, 
Figure 2: Comparative cytotoxicity of auranofin and other gold compounds (A) and classical chemotherapeutic agents 
(B) on cell growth of A2780 and A2780/AF-R cells. Data are means ± standard error derived from at least three independent 72-h 
drug exposure experiments. CRI, cross-resistance index; *p<0.001; **p≤0.05.
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results confirmed mRNA observations. Downregulation 
of SLC22A1 and SLC47A1 proteins in A2780/AF-R 
compared with A2780 cells was observed. P-gp expression 
was negligible in A2780 sensitive cells but was detectable 
at low levels in A2780/AF-R cells (Figure 5).
Reversal of auranofin resistance by verapamil
Verapamil abrogates efflux of anticancer drugs 
mediated by P-glycoprotein (P-gp) by competitive inhibition 
of drug transport. Since the A2780/AF-R displayed 
characteristics of drug accumulation compatible with the 
classical multi-drug resistance phenotype mediated by 
the overexpression of P-gp and other ABC transporters, 
verapamil was used to investigate its ability to reverse 
auranofin resistance in vitro. Results showed that verapamil 
partially reverted the resistant phenotype. In A2780/AF-R, co-
exposure of auranofin with verapamil 5, 10, 20 μM resulted 
in a 2.7-, 2.9- and 4.8-fold increase in the cytotoxicity of 
auranofin, respectively (Figure 6). No substantial differences 
in the growth inhibitory effects of auranofin were observed 
after co-exposure with verapamil in the auranofin sensitive 
cell line (i.e. 1.2-fold cytotoxicity increase following the 
addition of verapamil 5, 10, 20 μM) (Figure 6).
Activity of thioredoxin reductase
To evaluate a potential role of thioredoxin reductase 
(TrxR) in the acquired resistance to auranofin, its activity was 
investigated in both cell lines. Results showed that cellular 
TrxR activity was moderately higher in A2780/AF-R cells 
compared with A2780 cells (1.8-fold variation) (Table 2).
Intracellular glutathione levels
To investigate whether putative increased 
intracellular glutathione levels may contribute to the 
development of resistance to auranofin, basal total and 
reduced glutathione was evaluated in the auranofin 
sensitive and resistant cell lines. No difference was 
observed in total and reduced intracellular glutathione 
levels in A2780/AF-R compared to A2780 cells (Table 3). 
These results do not show correlation between 
glutathione and auranofin resistance in A2780/AF-R cells 
characterized by a high transport deficit.
DISCUSSION AND CONCLUSIONS
The development of resistance to anticancer 
agents is the main determinant of failure of anticancer 
chemotherapy in initially drug sensitive cancers [29]. 
In vitro human cell lines resistant to anticancer drugs 
represent useful models to study the mechanisms of drug 
action and tumour resistance. This is the first investigation 
describing a human tumour cell line with acquired 
resistance to a gold compound.
The human ovarian A2780 cell line, intrinsically 
sensitive to cisplatin, was used to develop an auranofin 
resistant cell line. Following stepwise selection with 
auranofin, an about 22-fold resistant subline (A2780/
AF-R) was obtained. Auranofin is currently undergoing 
clinical trial investigations in various types of cancers 
including ovarian cancer [10]. It also represents a 
reference compound when pharmacology of gold-based 
compounds is investigated.
The cytotoxic activity of a series of gold (I) and gold 
(III) compounds, platinum compounds and other cytotoxic 
anticancer agents characterized by different mechanisms 
of action against auranofin-resistant A2780/AF-R cells 
was tested. Resistance to auranofin in the A2780/AF-R 
cell line was associated with a low level of cross-resistance 
to three of the gold compounds tested (i.e. Aubipyc, 
Au2Phen2, and Au(NHC)Cl) as well as to oxaliplatin, 
Figure 3: Cellular gold accumulation in A2780 and A2780/AF-R. Cellular gold accumulation after exposure to 10μM auranofin 
ranging from 0 to 480 min in A2780 (black curve) and A2780/AF-R (red curve) cells. One representative experiment performed in duplicate.
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Figure 4: Up- and down-regulated genes in A2780/AF-R compared with A2780 cells. Relative mRNA expression levels of 
study genes according to 18S mRNA in A2780 (white bars) and A2780/AF-R (black bars). *>3-fold up or down-regulation of A2780/AF-R 
compared with A2780.
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melphalan, doxorubicin, etoposide, vinblastine, and 
paclitaxel. Lack of cross-resistance was observed against 
the other gold compounds and anticancer agents tested.
Knowledge of the cellular pharmacology of 
auranofin in experimental tumour models is still limited 
and little information is available on the mechanisms of 
tumour resistance to gold compounds [16]. The cytotoxic 
effects of auranofin appear to be directly related with 
the cellular content of auranofin-derived gold [5]. Also, 
in cultured human normal HE epithelial cells following 
stepwise selection for resistance to auranofin it was shown 
that maintenance of gold concentrations at a low level 
was a mechanism contributing to the observed cellular 
acquired resistance to auranofin [27]. Our data showed 
that intracellular gold accumulation during an 8-hour drug 
exposure time was markedly reduced in A2780/AF-R cells 
as compared to A2780 cells. This strongly suggests that 
the reduced sensitivity to auranofin is primarily due to a 
reduced steady-state cellular content of auranofin.
At present, only limited information is available 
on the mechanisms of intracellular uptake and 
accumulation of gold compounds [30]. Due to the 
ability of gold compounds to interact with thiol groups, 
transport through a thiol-shuttle has been suggested also 
involving reversible binding to serum albumin [31]. 
More recently, processes potentially involved in gold 
compound transport that include both influx and efflux 
systems have been hypothesized [32] on the basis of 
information available for platinum compounds [33, 34], 
Influx transporters comprising copper transporter (CTR) 
proteins and organic cation transporters (OCTs) are 
involved in the uptake of platinum compounds. Efflux 
transporters including adenosine triphosphate (ATP) 
binding cassette (ABC) multidrug transporters, copper-
transporting P-type adenosine triphosphatases (ATPases) 
and multidrug and toxin extrusion (MATE) proteins are 
also involved in the extrusion of these metal compounds. 
Endocytotic processes mediated by clathrin vesicles or by 
Na+/K+ ATP-ases and micropinocytosis involving a Na+/
H+ exchanger and PKI3CA in the signalling cascade have 
also been postulated to be involved in intracellular metal 
accumulation [32].
Our analysis of mRNA expression of genes 
potentially involved in cell transport or trafficking of gold 
compounds showed variations in 13 out of 24 genes in 
A2780/AF-R cells compared with A2780 cells. Seven genes 
were up-regulated and 6 genes were down-regulated.
It is known that the physiological role of members 
of the SLC family is heterogeneous since some of them 
are involved in the influx or efflux of organic cations or 
anions or in both these processes [35]. The organic cation 
transporters OCT1 and OCT2 (encoded by SLC22A1 
and SLC22A2, respectively) play an important role 
in the cellular uptake of some gold (I) N-heterocyclic 
carbene complexes (e.g. chlorido-[1,3-dimethyl-4,5-
diarylimidazol-2-ylidene] gold complexes) [32].
We observed a downregulation of SLC22A1 both at 
mRNA and protein expression level in A2780/AF-R cells 
Table 1: Genes associated with resistance to auranofin as measured by RT-PCR analysis
Gene name Description Fold change
Up-regulated genes
ABCC3 ATP binding cassette subfamily C member 3 2.1 x106
ABCB1 ATP binding cassette subfamily B member 1 5.2 x 103
SLC22A3 Solute carrier family 22 member 3 1.2 x103
ABCC2 ATP binding cassette subfamily C member 2 48.0
SLC31A2 Solute carrier family 31 member 2 6.3
CLTD Clathrin, heavy chain-like 1 3.4
CLTB Clathrin, light chain B 3.3
Down-regulated genes
SLC47A1 Solute carrier family 47 member 1 1.4x103
SLC22A1 Solute carrier family 22 member 1 21.9
ATP1A3 ATPase, Na+/K+ transporting, alpha 3 11.6
ABCG2 ATP-binding cassette, sub-family G member 2 11.2
SLCO1B1 Solute carrier organic anion transporter family member 1B1 4.1
PIK3CA Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha 3.4
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Figure 5: Variation of protein expression levels of selected transporters. Protein levels of SLC22A1, SLC47A1 and P-gp were 
determined by Western blotting. β-actin was included as a loading control.
Figure 6: Modulation of P-glycoprotein-mediated resistance in A2780/AF-R and A2780 by verapamil. Dose-response 
curves for auranofin (from 0.1 to 100 μM with or without verapamil (5, 10 or 20 μM) in A2780 (solid curves) and A2780/AF-R (dashed 
curves) cells are shown. Open or solid circles, 0 μM verapamil; open or solid squares, 5 μM verapamil; open or solid up triangles, 10 μM 
verapamil; open or solid down triangles, 20 μM verapamil. Data are means ± standard error derived from three independent 72-h drug 
incubation experiments.
Table 2: Basal thioredoxin reductase activity in A2780 and A2780/AF-R cells
Cell lines TrxR activity





TrxR, thioredoxin reductase; SD, standard deviation; n, number of independent experiments
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compared to A2780 cells. These findings suggest that OCT1 
(SLC22A1) may contribute to the uptake of auranofin and 
to resistance to this drug. In addition, it has been shown that 
oxaliplatin is an excellent substrate for OCT1 [36]. Thus, 
overexpression of SLC22A1 could explain at least in part 
the observed cross-resistance to this drug in A2780/AF-R 
cells. While SLC22A2 mRNA expression was unchanged, 
the expression of SLC22A3 gene, encoding for OCT3, was 
higher in A2780/AF-R cells compared with A2780 cells. It 
has been suggested that oxaliplatin is transported by OCT3 
[37] and that this transporter contributes to accumulation 
of this drug into cancer cells [38]. However, it has also 
been shown that intracellular accumulation of oxaliplatin 
is mainly due to increased expression of OCT2 rather 
than OCT3 or other OCTs as it occurs for other platinum 
compounds [39]. No information is available on the role 
of OCT3 in the transport of gold compounds or other 
anticancer drugs. Our results do not support a role of OCT3 
in the resistance to auranofin.
The copper transporter CTR1, codified by SLC31A1, 
has also been suggested to be involved in the uptake 
and accumulation of gold (I) N-heterocyclic carbene 
complexes [32]. The expression of SLC31A1 was found 
slightly downregulated (2.9-fold) in A2780/AF-R cells 
compared to A2780 cells. This could be related to the 
reduced gold accumulation and cytotoxicity of auranofin 
observed in A2780/AF-R cells. The role of CTR2 in the 
uptake and accumulation of gold compounds is currently 
unknown. A modest upregulation of SLC31A2 gene 
expression in A2780/AF-R cells compared to A2780 cells 
was observed. The contribution of this gene up-regulation 
to the accumulation and cytotoxicity of auranofin remains 
undefined.
Cisplatin and carboplatin [33, 40] and to a lesser 
extent oxaliplatin [41] are substrate of CTR1. Cisplatin 
and carboplatin are also substrates of CTR2. No clear 
correlation between observed CTR1 and CTR2 expression 
levels and sensitivity/resistance patterns to platinum 
compounds tested can be established.
MATE transporters are responsible for the excretion 
of xenobiotic organic cations in the kidney and liver. 
MATE1 encoded by SLC47A1 is also expressed in other 
tissues and is involved in the renal accumulation and 
nephrotoxicity of platinum agents [42]. The expression 
of SLC47A1 gene and that of its transcript was down-
regulated in A2780/AF-R cells compared with A2780 
cells. This data may explain the reduced cytotoxicity of 
oxaliplatin in A2780/AF-R cells and suggests a potential 
role of MATE1 also in auranofin transport and resistance.
Organic anion transporting polypeptides (OATPs) 
belonging to the SLCO subfamily play a relevant role 
in transporting endo- and xenobiotics, including several 
anticancer drugs, across plasma membranes. SLCO1B3 
gene overexpression was associated with increased 
cellular accumulation of platinum and increased 
sensitivity to platinum anticancer drugs in human 
tumour cell lines [43]. No difference in the expression of 
SLCO1B3 in A2780/AF-R cells compared with A2780 
cells was observed. A decrease in the expression of 
SLCO1B1 in A2780/AF-R cells compared with A2780 
cells was instead shown. Although the role of SLCO1B1 
in the transport of metal compounds has not been 
investigated, a contribution of downregulation of this 
carrier to tumour resistance to auranofin and oxaliplatin 
in A2780 cells cannot be ruled out.
ATP binding cassette transporters are members 
of a large family of cell membrane efflux transporters. 
Overexpression of these transporters confers resistance to 
a large series of structurally unrelated anticancer drugs [44].
P-gp, codified by the ABCB1 gene, is responsible 
for the development of the multidrug resistance cancer 
phenotype [45, 46]. Increased ABCB1 mRNA expression 
level in A2780/AF-R cells as compared to A2780 cells 
was observed. This was confirmed also at the protein 
level. Auranofin sensitivity was partially restored after 
co-exposure of the resistant cell line to verapamil and 
auranofin. These findings suggest a contribution of 
this transporter in the efflux of auranofin and in the 
development of acquired resistance to this drug. Little 
information is available on the role of P-gp in the cellular 
kinetics and activity of gold compounds. A recent 
published study showed that an investigational carbene 
gold compound was active in two human leukemia 
sublines resistant to either vincristine or daunorubicin, due 
to overexpression of P-gp [47]. No difference in the gold 
uptake between these resistant leukaemia cell lines and 
their sensitive counterpart was observed, conveying that 
the study gold compound was not a P-gp substrate [47]. 
Table 3: Basal intracellular glutathione levels in A2780 and A2780/AF-R cells
Cell lines GSH + GSSG
μg/106 cells ± SD
GSH





GSH + GSSG, total glutathione; GSH, reduced glutathione; SD, standard deviation; n, number of independent experiments
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These data suggest that different gold compounds may 
undergo different mechanisms of drug efflux.
Since ABCB1 overexpression is involved in tumour 
resistance to several anticancer drugs including vinca 
alkaloids, doxorubicin, etoposide and taxanes, low grade 
cross-resistance to some of these drugs observed in 
A2780/AF-R cells might be mediated by increased P-gp 
levels.
Similar considerations may be done for cross-
resistance to oxaliplatin and melphalan observed in A2780/
AF-R cells. In colon cancer cell lines the overexpression of 
ABCB1 was associated to oxaliplatin resistance [48]. Also, 
increased ABCB1 expression and decreased intracellular 
melphalan accumulation as well as increased resistance to 
this drug in a human HL-60 promyelocytic leukaemia cell 
line have been reported [49].
We observed an increase in the mRNA expression of 
ABCC2, a member of the MRP subfamily, in A2780/AF-R 
cells as compared to A2780 cells. In tumour models the 
overexpression of this transporter has been associated with 
the development of tumour resistance to several anticancer 
agents including platinum compounds, vinblastine and 
etoposide [50]. In keeping with these data, resistance to 
these drugs was observed in A2780/AF-R cells. A high 
level of ABCC3 expression was observed in A2780/
AF-R cells as compared to A2780 due to the negligible 
expression of this gene in A2780 cells. Resistance to 
etoposide has been associated to ABCC3 overexpression 
[51], thus resistance to this drug in A2780/AF-R cells may 
be in part due to this occurrence.
Our association data suggest a role of these ATP 
binding cassette transporters also in the development of 
acquired resistance to auranofin.
Breast cancer resistance protein (BCRP) encoded by 
ABCG2 displays an important role in resistance to several 
anticancer drugs, including camptothecins, antifolates and 
anthracyclines. We observed down-regulation of ABCG2 
in A2780/AF-R cells compared to A2780 cells but no 
meaningful association could be established with observed 
sensitivity/resistance patterns. The involvement of BCRP 
in the transport of platinum and other metal drugs has 
in fact been not ascertained. In particular, contradictory 
results have been reported on the role of this transporter in 
the development of oxaliplatin resistance.
Following uptake by CTRs, intracellular copper and 
other metals are tightly controlled and shuttled through 
subcellular compartments via interactions with copper 
chaperones and secreted. Homeostasis of copper is 
maintained by antioxidant 1 (ATOX1) that transfers copper 
to the copper transporting P1B-type ATPases ATP7A and 
ATP7B. It has been shown that overexpression of ATOX1, 
ATP7A and ATP7B reduces cisplatin accumulation 
and sensitivity [52-54]. No substantial differences in 
the mRNA expression of these genes were observed in 
A2780/AF-R cells compared to the A2780 cells and no 
association with resistance to auranofin was ascertained.
ATP1A1, ATP1A2 and ATP1A3 genes encode 
for isoforms of Na+/K+-ATPase, a membrane protein 
responsible the electrochemical Na+/K+ gradients 
essential for Na+-coupled transport of various organic 
and inorganic molecules. We observed downregulation 
of ATP1A3 gene expression and no significant change in 
the mRNA expression of ATP1A1 and ATP1A2 genes in 
A2780/AF-R cells compared to A2780 cells. Very limited 
data are available on the involvement of these proteins in 
the transport of anticancer agents including metal drugs. 
However, it has been shown that inhibition of Na+/K+-
ATPase with ouabain reduces platinum accumulation in 
A2780 cells and that lower expression of Na+/K+-ATPase 
alpha-1 subunit is associated with resistance to cisplatin 
[55]. Our results do not allow to speculate on the potential 
role of these proteins in the resistance to auranofin and 
other drugs tested.
To verify the hypothesis that selective inhibition 
of clathrin function reduces cytotoxic activity of 
gold compounds as a consequence of reduced gold 
uptake through clathrin-mediated endocytosis [32], we 
investigated the potential association of the expression of 
clathrins A (CLTA), B (CLTB), C (CLTC) and D (CLTD) 
with auranofin resistance. The observed modest increase 
of CLTB and CLTD expression levels in the auranofin 
resistant cell line compared with the auranofin sensitive 
cell line do not support the hypothesis that gold uptake 
may be mediated by clathrin endocytosis.
It was also shown that a modest attenuation of the 
cytotoxicity of some gold carbene complexes occurred 
upon addition of wortmannin, a fungal metabolite inhibitor 
of PIK3CA [32]. Since activated PIK3CA is involved in the 
signalling cascade leading to macropinosome formation, 
it was speculated that this finding may be due to specific 
inhibition of this putative mechanism of gold compound 
uptake. However, no information is available on its role 
in the transport of anticancer agents with the exception 
of macromolecular conjugated drugs. Also, PIK3CA is 
not only involved in intracellular trafficking but also in 
several other processes including cell growth, proliferation, 
differentiation, motility and survival. The mRNA expression 
of PIK3CA was modestly decreased in A2780/AF-R cells 
compared to A2780 cells. This borderline association does 
not allow us to conclude that macropinocytosis play a role 
in the uptake of gold compounds.
Due to the recognized ability of auranofin to 
inhibit TrxR, we verified if alterations in TrxR enzymatic 
activity may contribute to the mechanism of acquired 
resistance to auranofin. The moderately higher activity 
(< 2-fold) observed in the A2780/AF-R cells compared 
with A2780 cells might reflect a concurrent adaptative 
cellular response to stepwise selection with increasing 
auranofin concentrations during time, while high level 
resistance developed due to transport defects. In vitro 
tumour sensitivity and resistance to auranofin and platinum 
compounds have been associated to changes in intracellular 
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TrxR activity. High level (≥ 10-fold) intrinsic resistance to 
auranofin has been associated to a substantial increase in 
TrxR activity in non-small cell lung cancer cell lines [56]. 
Also, low-intermediate level acquired resistance (about 2-5-
fold) to cisplatin associated to slight-moderate increases 
(1.3-2-fold) in TrxR activity have been reported in various 
tumour cell lines [57-59]. No cross-resistance with cisplatin 
was however observed in our model. It is conceivable that 
this mechanism may have contributed at least in part to 
auranofin resistance observed in A2780/AF-R cells.
Thiols may play an important role in the molecular 
mechanisms of resistance to anticancer drugs, including 
metal drugs. Glutathione is the main cellular thiol 
that interacts with copper and platinum-based drugs. 
It is common to find elevated glutathione levels in 
cisplatin resistant tumour models [60]. No differences 
in intracellular glutathione content between A2780/
AF-R cells and A2780 cells were observed. Thus, no 
contribution of this mechanism of resistance was noted.
Our results support the knowledge that transport of 
auranofin is a critical determinant of cytotoxicity of this 
drug in cancer cells. An about complete abolition (>95%) 
of gold accumulation occurred in A2780/AF-R cells. 
This was associated to a high level (>20 fold) of acquired 
resistance. The only previously reported data do not relate 
to a tumour model (HE cells) [27]. In this study, the HE 
auranofin-resistant subline was selected by a stepwise 
process similar to that used in the present investigation, 
reaching a somewhat lower drug concentration (2 μM). 
Following a 24-h auranofin exposure, cellular gold content 
observed in auranofin-resistant HE cells were only one-
half of those observed in parental HE cells.
The observed highly reduced accumulation of gold 
in A2780/AF-R cells was associated to expression changes 
of various influx and efflux transporters. In addition, 
verapamil reverted only partially resistance to auranofin 
at concentrations able to abrogate almost completely 
vinblastine and doxorubicin resistance in the classical 
multidrug resistance phenotype. This provides evidence 
that multiple drug transporters may act as mediators of 
auranofin and possibly of other gold compound transport 
in cancer cells. However, the relative contribution of the 
single transporters investigated in this study remains to be 
settled by future studies. An additional contribution to the 
degree of auranofin resistance by the observed moderately 
increased TrxR activity may not be ruled out.
Our findings warrant further investigation into the 
molecular mechanisms mediating transport of auranofin 
in view of a potential role of this agent in the treatment 
of human cancer. The understanding of gold transportome 
by means of transcriptomics analysis is ongoing at our 
laboratory as well as the attempt to evaluate the relative 
contribution of single processes potentially involved by 
functional studies with specific transport inhibitors or 
gene silencing of transporters and protein expression 
studies. This will provide crucial insights into the cellular 
pharmacology of auranofin and information useful for the 
design of new gold complexes for clinical application.
MATERIALS AND METHODS
Drugs and supplies
Auranofin was obtained from Vinci Biochem 
(Vinci, Italy); Auoxo6 [61] and Au2Phen2 [62], two 
dinuclear gold (III) compounds, and Aubipyc [63], 
an organogold (III) complex, were provided by Prof. 
M.A. Cinellu. AuL12 [64], a gold (III) dithiocarbamate 
complex, was provided by Prof. D. Fregona. The two 
gold (I) carbene compounds, namely chlorido (1-butyl-
3-methyl-imidazole-2-ylidene) gold (I) (Au(NHC)Cl)) 
and bis(1-butyl-3-methyl-imidazole-2-ylidene) gold (I) 
(Au(NHC)2) [65], were provided by Prof. C. Gabbiani. 
Cisplatin, oxaliplatin, carboplatin, melphalan, vinblastine, 
etoposide, doxorubicin, paclitaxel, docetaxel, verapamil 
and sulforhodamine B (SRB) were obtained from Sigma 
(Milan, Italy). All the other chemicals were of analytical 
grade. RPMI 1640 cell culture medium, foetal calf serum 
(FCS), and phosphate-buffered saline were obtained from 
Celbio (Milan, Italy).
Cell lines and culture conditions
The human auranofin-sensitive parental ovarian 
cancer A2780 cell line was a gift of Prof. Kevin Scanlon 
(Keck Graduate Institute, CA, U.S.A). The auranofin-
resistant cell subline (A2780/AF-R) was established from 
the parental sensitive cell line as described in the following 
paragraph. Cell lines were maintained in RPMI-1640 
supplemented with 10% FCS and antibiotics (penicillin, 
100 U/ml; streptomycin, 100 μg/ml) at 37°C in a 5% CO2 
humidified atmosphere and subcultured twice weekly.
Development of resistance to auranofin
A2780/AF-R cells were obtained by a continuous 
exposure of the parental sensitive A2780 cells to stepwise 
increasing auranofin concentrations. Initially, parental 
sensitive cells were grown in standard medium containing 
a low (sublethal) concentration of auranofin (100 nM). 
After 3 or 4 passages in this growth condition, auranofin 
concentration was increased in a stepwise manner up to 6 
times until a 7 μM final concentration. This concentration 
level was achieved in an 8-month selection period.
Cytotoxicity and drug resistance reversal assays
The growth inhibitory effects of auranofin as well as 
of other six gold compounds and selected cytotoxic drugs 
against A2780/AF-R cells were determined by the SRB assay 
[66] to assess the degree of acquired resistance to auranofin 
and the potential occurrence of cross-resistance or collateral 
sensitivity to other drugs. Also, the potential modulation 
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of resistance to auranofin by verapamil, a calcium channel 
blocker capable of reversing the classical multidrug resistance 
phenotype, was determined by the same assay.
Exponentially growing cells were seeded in 96-well 
plates in RPMI 1640 supplemented with 10% FCS at a 
plating density of 4x103 cells/well.
After 24 hours, A2780 and A2780/AF-R cells were 
exposed to increasing concentrations of gold compounds 
or other drugs (cisplatin, carboplatin, oxaliplatin, 
melphalan, vinblastine, doxorubicin, paclitaxel, docetaxel 
and etoposide). Concentrations ranged from 1 nM to 100 
μM and each concentration was tested in triplicate.
To assess the reversal of resistance to auranofin by 
verapamil, cells were pre-treated with this drug 15 min before 
auranofin exposure and co-exposed to verapamil during 
auranofin exposure. Concentrations of verapamil used (i.e. 5, 
10, 20 μM) were not cytotoxic (lower than IC20).
In all cases, after 72-hour drug exposure, cells were 
fixed with 10% trichloroacetic acid and stained with 0.4% 
SRB in 1% acetic acid. The SRB fixed to the cells was 
dissolved in 10 mM Tris-HCl and absorbance was read 
on an automated plate reader at a wavelength of 540 nm.
The IC50 drug concentration resulting in a 50% 
reduction in the net protein content (as measured by SRB 
staining) in drug treated cells as compared to untreated 
control cells was determined. All the reported IC50 values 
represent the mean of at least three independent experiments.
The degree of acquired resistance to auranofin in 
A2780/AF-R cells was calculated as the ratio between IC50 
values of A2780/AF-R and the IC50 value of the parental 
cell line (resistance index, RI).
The degree of cross-resistance to the other gold 
compounds or cytotoxic agents tested in A2780/AF-R 
cells was calculated as the ratio between IC50 values of 
A2780/AF-R and those of the parental cell line (cross-
resistance index, CRI).
In the experiments of auranofin resistance reversal, 
the reversal fold (RF) values indicating the potency of 
reversal were calculated by dividing IC50 of auranofin 
alone by IC50 of auranofin in combination with verapamil.
Determination of cellular gold accumulation
A2780/AF-R and parental A2780 cells were seeded in 
duplicate in 60 mm2 Petri dishes in RPMI 1640 supplemented 
with 10% FCS at plating densities of 2x106 cells/dish 
following a 7-day culture period in drug-free medium.
After 24 hours, auranofin was added at high 
concentration (10 μM), then cells were incubated for 0, 
2.5, 5, 10, 20, 40, 60, 80, 120, 240, and 480 min. The 
cell monolayers were washed 3 times with PBS and, after 
trypsinization, cells were pelleted, counted and then lysed 
by cell lysis buffer.
The gold content was determined following a 
previously published protocol [67] with some slight 
modifications. Each sample of pellet was recovered in a 
PE vial and digested in a thermo-reactor at 80°C for 8 
h with 1.0 mL of HNO3 69.5% suprapure grade. After 
digestion, samples were diluted exactly to 6 mL with 
ultrapure water (≤18 MΩ). The determination of gold 
content in these solutions was performed in duplicate 
by a Varian 720-ES Inductively Coupled Plasma Atomic 
Emission Spectrometer (ICP-AES). The calibration curve 
of gold was obtained using known concentrations of a 
gold ICP standard solution purchased by Sigma-Aldrich. 
Moreover, each sample were spiked with 1 ppm of Ge 
used as an internal standard. The wavelengths used for 
Au determination were 242.795 and 267.595 nm whereas 
for Ge the line at 209.426 nm was used. The operating 
conditions were optimized to obtain maximum signal 
intensity and, between each sample, a rinse solution 
containing 1.0 mL of HNO3 69.5% suprapure grade and 
5.0 mL of ultrapure water was used in order to avoid any 
“memory effect”.
The cellular gold content was calculated as the mean 
of two independent determinations and referred as total 
pmol Au/106 cells. The area under the curve (AUC) of 
intracellular gold content was calculated by Graph Pad 
Prism Software (Inc., La Jolla, CA).
Gene expression analysis
Overall, we analysed the expression of 24 mRNA 
genes involved in cellular transport and/or trafficking 
pathways. Genes were candidate on the basis of their 
known role in cell influx and/or efflux of metals (e.g. 
copper), metal-based anticancer drugs (e.g. platinum 
drugs), and more in general in tumour drug resistance. 
According to such criteria we evaluated the gene 
expression of 8 transporters belonging to the solute 
carrier family (SLC22A1, SLC22A2, SLC22A3, SLC31A1, 
SLC31A2, SLCO1B1, SLCO1B3 and SLC47A1), 5 
ATP-binding cassette transporters (ABCB1, ABCC1, 
ABCC2, ABCC3, ABCG2), 2 copper transporter ATPases 
(ATP7A, ATP7B), one copper chaperone (ATOX1), 
and 3 isoforms of Na+/K+ ATPase (ATP1A1, ATP1A2, 
ATP1A3). In addition, we analysed the mRNA expression 
of 4 clathrin isoforms (CLTA, CLTB, CLTC, CLTD), 
that are physiologically involved in mechanisms of 
internalization (e.g. endocytosis), and of PI3KCA gene 
that plays a key role in the signalling cascade associated 
with macropinocytosis. To identify genes with biologically 
significant expression changes, a 3-fold change was 
considered as an arbitrary cut-off [68].
RNA preparation and amplification
Total RNA was isolated from A2780 and A2780/
AF-R cell lines as previously described using a NucleoSpin® 
RNA Protein Kit (Macherey-Nagel, Germany) according to 
instruction’s manual. The RNA was quantified by Qubit™ 
3.0 Fluorometer (Invitrogen, USA). 500ng of total RNA 
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were retro-transcribed using iScript (Bio-Rad, USA) 
and amplified with specific primers listed in Table 4. All 
primers were purchased from IDT (IDT, Germany). PCR 
amplification was carried out by means SsoAdvancedTM 
Universal SYBR® Green Supermix (Bio-Rad, USA) 
according to manual instruction using the RotorGene 3000 
Instrument (Qiagen Germany). Ribosomal 18s rRNA was 
used as the normalizer. Quantitative PCR was performed 
using the following procedure: 98°C for 2 min, 40 cycles 
of 98°C for 5 sec, 60°C for 10 sec. The program was set 
to reveal the melting curve of each amplicon from 60°C to 
95°C with a read every 0.5°C.
Western blot analysis
60 μg of total proteins were separated by NuPAGE 
12% Bis-Tris Gel and electroblotted (Turbo-Blot apparatus; 
Bio-Rad, USA) onto nitrocellulose membranes (Bio-Rad, 
USA) according to instruction’s manual. The following 
antibodies were used: SLC22A1, SLC47A1, ABCB1 and 
β-Actin (GeneTex, USA). The membranes were incubated 
over-night at 4C°. After incubation membranes were washed 
with TPBS and incubated 1 h in TPBS/5% milk containing 
the corresponding peroxidase-conjugated secondary 
antibody (1:2000) (Bio-Rad, USA). After washing in TPBS, 
ECL (Bio-Rad, USA) was used to visualize the peroxidase-
coated bands by means of ChemiDoc MP Imaging System 
(Bio-Rad, USA). Densitometric analysis was performed by 
Quantity One software (Bio-Rad, USA).
Glutathione assay
Glutathione content in A2780/AF-R and A2780 cells 
was determined by a spectrophotometric method. Briefly, 




























cells were seeded in 60 mm2 Petri dishes at a plating 
density of 1x106 cells/well and incubated for 48 h. Cells 
were harvested and counted, the levels of intracellular total 
glutathione (GSH + GSSG) and of the reduced glutathione 
form (GSH) were measured using ApoGSHTM Glutathione 
Colorimetric Detection Kit (BioVision, California, USA).
Serial dilutions of GSH + GSSG and GSH were used 
to generate corresponding standard curves. GSH + GSSG 
and GSH concentrations were expressed as μg/106 cells.
Thioredoxin reductase activity
Thioredoxin reductase activity was determined 
spectrophotometrically in cell extracts by the Thioredoxin 
Reductase Assay Kit (Sigma-Aldrich, St. Louis, MO). 
A2780 and A2780/AF-R cells were seeded in 100 mm2 
Petri dishes at a plating density of 2x106 cells/well and 
incubated for 48 h. Cells were harvested, counted and 
washed with PBS. Samples were lysed with a 500 
μl CelLytic Extraction Reagent (Sigma-Aldrich, St. 
Louis, MO) containing 50 μl of a protease inhibitor 
cocktail (Sigma-Aldrich, St. Louis, MO). After 15 min 
of incubation on a shaker, lysates were centrifuged at 
12,000 g for 15 min to pellet cell debris and the obtained 
supernatants were tested for enzyme activities. Enzymatic 
activity was assessed by measuring the absorbance at 
412 nm using a microplate reader. The Bradford Reagent 
(Sigma-Aldrich, St. Louis, MO) was used to determine 
protein concentrations. Results are the mean of three 
independent experiments.
Statistical analysis
t-Tests were used for pairwise comparisons. P values 
<0.05 were considered statistically significant. All data 
were analysed using Graph Pad Prism version 5 (Graph 
Pad Prism Software Inc., La Jolla, CA).
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